Neuron Alzheimer

Clinical trials of experimental therapy with gantenerumab failed to show any improvement in Alzheimer’s memory loss

The manufacturer claimed Monday that gantenerumab was an experimental treatment that failed to aid people with Alzheimer’s disease or who were at the beginning stages of the disease.

Gantenerumab belongs to a group of injectable drugs that are designed to remove beta-amyloid, a sticky protein piece from the brain. Alzheimer’s disease is known for beta-amyloid buildup.

While most of these drugs are effective in clearing beta-amyloid, many have failed to show any real benefits to patients. The patient’s brain function and memories don’t improve despite being treated.

Roche Monday said that gantenerumab seems to have less beta-amyloid in the brains than expected. Roche said that the Phase 3 results of its Graduate trials were difficult but necessary to share.

In a press release, Dr. Levi Garraway (Roch’s chief medical officer, and head of global product design), stated that “so many of our family members have been directly affected with Alzheimer’s,”. Although the GRADUATE results were not as expected, we are proud that we have provided a high-quality, clear, comprehensive Alzheimer’s dataset for the field. We look forward to sharing our findings with the community in the future as we search for new treatments.

Roche stated that it will share additional findings from the study at a future medical conference.

Positive results were obtained for lecanemab, a beta-amyloid-reducing drug. The results for Gantenerumab are similar to those for lecanemab. Biogen and Eisai announced that lecanemab had reduced the brain decline in Alzheimer’s disease by approximately 27% when compared to a placebo. Experts believe that this level of benefit is comparable to that of Aduhelm, a controversial Alzheimer’s drug that was approved by the US Food and Drug Administration despite the lack of support from independent advisers.

Professor of psychiatry at Johns Hopkins School of Medicine Dr. Constantine Lyketsos stated that gantenerumab might have had a similar benefit to Aduhelm and lecanemab if it had removed as many beta amyloids as the company claimed.

Lyketsos, who wasn’t involved in the research, stated that there was a “very modest, but not clinically meaningful effect”.

In a statement, the Alzheimer’s Association stated that while Roche’s results are disappointing, it is still hopeful for this treatment class.

“Each anti-amyloid treatment is different, so research must continue into their safety and effectiveness. Maria Carrillo (the nonprofit’s chief scientist officer) stated in the statement that it is crucial to evaluate each treatment individually.

According to the Alzheimer’s Association, an estimated 6.5 million Americans will have Alzheimer’s disease by 2022.

About The Author

Leave a Comment

Scroll to Top